Exemestane in Advanced and Recurrent Endometrial Carcinoma
NCT ID: NCT01965080
Last Updated: 2013-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
52 participants
INTERVENTIONAL
2004-03-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: Treatment With Exemestane can give a response rate of at least 30%
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients were grouped according to estrogen receptor status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exemestane
Exemestane 25 mg daily
Exemestane
One tablet Exemestane 25 mg daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exemestane
One tablet Exemestane 25 mg daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Endometrioid histology
* Age above 18 years
* Post menopausal status
* Performance status 0-2
* Informed consent
Exclusion Criteria
* History of thromboembolic signs
* Other primary hormonal therapy
* Patients With symptomatic brain metastasis
* Severe hepatic or renal impairment
* Pregnancy, lactation or child bearing potential without adequate contraception
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gunnar Kristensen, MD, PhD
Role: STUDY_CHAIR
NSGO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Norwegian Radium Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrom B. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSGO-EC-0302
Identifier Type: -
Identifier Source: org_study_id